AP664A - Protection from viral infection by colonization of musocal membranes with genetically modified bacteria. - Google Patents
Protection from viral infection by colonization of musocal membranes with genetically modified bacteria. Download PDFInfo
- Publication number
- AP664A AP664A APAP/P/1997/001087A AP9701087A AP664A AP 664 A AP664 A AP 664A AP 9701087 A AP9701087 A AP 9701087A AP 664 A AP664 A AP 664A
- Authority
- AP
- ARIPO
- Prior art keywords
- bacteria
- virus
- transformed
- host
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/60—Isolated nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/401,070 US5733540A (en) | 1995-03-08 | 1995-03-08 | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
PCT/US1996/003151 WO1996027292A1 (en) | 1995-03-08 | 1996-03-08 | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
Publications (2)
Publication Number | Publication Date |
---|---|
AP9701087A0 AP9701087A0 (en) | 1997-10-31 |
AP664A true AP664A (en) | 1998-08-19 |
Family
ID=23586156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/1997/001087A AP664A (en) | 1995-03-08 | 1996-03-08 | Protection from viral infection by colonization of musocal membranes with genetically modified bacteria. |
Country Status (11)
Country | Link |
---|---|
US (1) | US5733540A (pt) |
EP (1) | EP0871363A4 (pt) |
JP (1) | JPH11501632A (pt) |
CN (1) | CN100519735C (pt) |
AP (1) | AP664A (pt) |
AU (1) | AU696449B2 (pt) |
BR (1) | BR9607146A (pt) |
CA (1) | CA2214723A1 (pt) |
EA (1) | EA000576B1 (pt) |
OA (1) | OA10741A (pt) |
WO (1) | WO1996027292A1 (pt) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737521B1 (en) * | 1990-05-11 | 2004-05-18 | The Rockefeller University | Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria |
US6130202A (en) * | 1990-07-20 | 2000-10-10 | Bayer Corporation | Antiviral methods |
US5547684A (en) * | 1993-02-10 | 1996-08-20 | Pharmec Company | Cosmetic composition containing a DNA-sodium salt and methods of making and using the same |
GB9521568D0 (en) * | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
US8563522B2 (en) * | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
US20020035071A1 (en) * | 1997-07-08 | 2002-03-21 | Josef Pitha | Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites |
US20060116330A1 (en) * | 1997-07-08 | 2006-06-01 | The Iams Company | Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
US7135191B2 (en) * | 1997-09-04 | 2006-11-14 | Zsolt Istvan Hertelendy | Urogenital or anorectal transmucosal vaccine delivery system |
BR9908267A (pt) * | 1998-02-27 | 2000-10-24 | Univ Pennsylvania | Plasmìdeo, composição farmacêutica, processos para induzir uma resposta imunológica em um indivìduo contra um imunógeno, para imunizar um indivìduo contra uma infecção por vìrus de herpes simples e para tratar um indivìduo que tem uma doença autoimune, vacina recombinante, e, patógeno atenuado vivo |
WO2000006764A1 (en) * | 1998-07-30 | 2000-02-10 | Wisconsin Alumni Research Foundation | Gastrointestinal bacterial antibody factories |
WO2000062758A1 (en) * | 1999-04-16 | 2000-10-26 | Osel, Inc. | A method for improving the half-life of soluble viral-specific ligands on mucosal membranes |
CN101912610A (zh) | 1999-06-24 | 2010-12-15 | 约翰·霍普金斯大学 | 用于预防hiv经上皮传播的组合物和方法 |
WO2002060390A2 (en) | 2001-01-04 | 2002-08-08 | Yale University | Induction of immune responses to isoaspartyl-modified antigens |
US7780961B2 (en) * | 2001-05-03 | 2010-08-24 | Actogenix N.V. | Self-containing Lactococcus strain |
US7101565B2 (en) | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
AU2003276822A1 (en) * | 2002-03-08 | 2004-02-02 | Osel, Inc. | Lactobacilli expressing biologically active polypeptides and uses thereof |
WO2004001020A2 (en) * | 2002-06-19 | 2003-12-31 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Methods and means to promote gut absorption |
CA2506031A1 (en) * | 2002-11-15 | 2004-06-03 | Vib Vzw | Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof |
US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
US20090208478A1 (en) * | 2003-10-24 | 2009-08-20 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
EP2418281B1 (en) | 2003-10-24 | 2016-06-01 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
US20050100559A1 (en) * | 2003-11-07 | 2005-05-12 | The Procter & Gamble Company | Stabilized compositions comprising a probiotic |
US20050158294A1 (en) * | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
US8894991B2 (en) * | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
US8877178B2 (en) * | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
US20050152884A1 (en) | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
ATE511848T1 (de) | 2004-08-25 | 2011-06-15 | Us Gov Health & Human Serv | Lebendige mikrobielle mikrobizide |
WO2006083516A2 (en) * | 2005-01-12 | 2006-08-10 | Osel, Inc. | Modified cyanovirin-n polypeptide |
DK1880001T3 (da) * | 2005-05-31 | 2011-09-12 | Iams Company | Feline probiotiske lactobacilli |
CA2607949C (en) * | 2005-05-31 | 2012-09-25 | Thomas William-Maxwell Boileau | Feline probiotic bifidobacteria |
JP5410759B2 (ja) | 2005-11-29 | 2014-02-05 | アクトジェニックス・エヌブイ | 抗原に対する粘膜寛容の誘導 |
EP2774621B1 (en) | 2007-01-25 | 2018-01-24 | Intrexon Actobiotics NV | Treatment of immune disease by mucosal delivery of antigens |
AU2008211600B8 (en) | 2007-02-01 | 2014-02-13 | Mars, Incorporated | Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts |
EP2273998A2 (en) * | 2008-04-04 | 2011-01-19 | Farallone Holdings Bv | Methods and materials for gastrointestinal delivery of pathogen/toxin binding agents |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
SI2556150T1 (sl) * | 2010-04-06 | 2016-12-30 | Vakzine Projekt Management Gmbh | Virusni delec, sproščen po infekciji sesalskih celic s človeškim citomegalovirusom (HCMV), ki vsebuje fuzijski protein, in uporaba le-tega |
IL208820A0 (en) | 2010-10-19 | 2011-01-31 | Rachel Teitelbaum | Biologic female contraceptives |
US10426761B2 (en) | 2011-04-19 | 2019-10-01 | Arms Pharmaceutical, Llc | Method for treatment of disease caused or aggravated by microorganisms or relieving symptoms thereof |
MX2013012151A (es) | 2011-04-19 | 2014-06-20 | ARMS Pharmaceutical LLC | Metodo para inhibir microorganismos dañinos y composicion de formacion de barreras para los mismos. |
WO2018183685A1 (en) | 2017-03-29 | 2018-10-04 | President And Fellows Of Harvard College | Methods of regulating gene expression in a cell |
CN111491657A (zh) | 2017-10-20 | 2020-08-04 | 哈佛学院院长及董事 | 用于异源蛋白质生产的人工分泌肽 |
EP3720458A4 (en) * | 2017-12-05 | 2021-12-08 | BioPlx, Inc. | METHODS AND COMPOSITIONS FOR PREVENTING MICROBIAL INFECTION |
WO2022020985A1 (zh) * | 2020-07-27 | 2022-02-03 | 上海市公共卫生临床中心 | 利用呼吸道上皮细胞膜防治呼吸道传染病的方法及应用 |
EP4130258A1 (en) | 2021-08-02 | 2023-02-08 | Evonik Operations GmbH | Microorganisms displaying viral decoy receptors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5348867A (en) * | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
WO1996002792A2 (en) * | 1994-07-15 | 1996-02-01 | Aalborg Industries A/S | A fluid-bed heat exchanger, fluid-bed combustion reactor systems and methods for the operation of a fluid-bed heat exchanger and a fluid-bed combustion reactor system |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE469875C (sv) * | 1991-07-25 | 1997-02-05 | Probi Ab | Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen |
JPH07504817A (ja) * | 1992-03-03 | 1995-06-01 | ザ ロックフェラー ユニヴァーシティ | B29(Ig‐βまたはIg−γ)を含むレセプタ複合体およびその利用 |
US5531988A (en) * | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Bacteria and immunoglobulin-containing composition for human gastrointestinal health |
-
1995
- 1995-03-08 US US08/401,070 patent/US5733540A/en not_active Expired - Lifetime
-
1996
- 1996-03-08 BR BR9607146A patent/BR9607146A/pt not_active Application Discontinuation
- 1996-03-08 EA EA199700215A patent/EA000576B1/ru not_active IP Right Cessation
- 1996-03-08 CA CA002214723A patent/CA2214723A1/en not_active Abandoned
- 1996-03-08 JP JP8527052A patent/JPH11501632A/ja not_active Ceased
- 1996-03-08 CN CNB961923911A patent/CN100519735C/zh not_active Expired - Fee Related
- 1996-03-08 AP APAP/P/1997/001087A patent/AP664A/en active
- 1996-03-08 WO PCT/US1996/003151 patent/WO1996027292A1/en active Application Filing
- 1996-03-08 EP EP96909613A patent/EP0871363A4/en not_active Ceased
- 1996-03-08 AU AU53044/96A patent/AU696449B2/en not_active Ceased
-
1997
- 1997-09-08 OA OA70073A patent/OA10741A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5348867A (en) * | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
WO1996002792A2 (en) * | 1994-07-15 | 1996-02-01 | Aalborg Industries A/S | A fluid-bed heat exchanger, fluid-bed combustion reactor systems and methods for the operation of a fluid-bed heat exchanger and a fluid-bed combustion reactor system |
Also Published As
Publication number | Publication date |
---|---|
WO1996027292A1 (en) | 1996-09-12 |
EP0871363A4 (en) | 2001-12-12 |
AU696449B2 (en) | 1998-09-10 |
CA2214723A1 (en) | 1996-09-12 |
BR9607146A (pt) | 1997-11-25 |
EP0871363A1 (en) | 1998-10-21 |
CN100519735C (zh) | 2009-07-29 |
CN1177909A (zh) | 1998-04-01 |
JPH11501632A (ja) | 1999-02-09 |
US5733540A (en) | 1998-03-31 |
OA10741A (en) | 2002-12-11 |
EA199700215A1 (ru) | 1998-02-26 |
AU5304496A (en) | 1996-09-23 |
AP9701087A0 (en) | 1997-10-31 |
EA000576B1 (ru) | 1999-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP664A (en) | Protection from viral infection by colonization of musocal membranes with genetically modified bacteria. | |
Lee et al. | Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice | |
Machuca et al. | Isolation of a novel bacteriophage specific for the periodontal pathogen Fusobacterium nucleatum | |
US8349586B1 (en) | Commensal strain of E. coli encoding an HIV GP41 protein | |
EP0437604B1 (en) | Recombinant poxvirus and streptococcal m protein vaccine | |
JP5683603B2 (ja) | Ebウィルスにより誘発される腫瘍に対する融合ポリペプチドとコリシンia変異体 | |
RU2771177C1 (ru) | Рекомбинантный вектор, содержащий иммуногенный белок вируса африканской чумы свиней, рекомбинантные бактерии и их применение | |
KR20040104936A (ko) | 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 | |
JP7426953B2 (ja) | 免疫原性組成物 | |
EP2474558B1 (en) | New antibiotic containing simulacrum antibody, preparation method and application thereof | |
CN101838658B (zh) | O型口蹄疫病毒变异株及其编码基因和应用 | |
WO2003106483A1 (fr) | Peptide anti-virus enveloppe recombine et sa preparation | |
Singh et al. | Role of Phage Therapy in COVID-19 Infection: Future Prospects | |
Wei et al. | The ΦCPG1 chlamydiaphage can infect Chlamydia trachomatis and significantly reduce its infectivity | |
JP2024512575A (ja) | 弱毒化されたレオウイルスベースのワクチン組成物及びその用途 | |
CN109206519B (zh) | 一种抗尿素酶b亚单位的纳米抗体及核酸分子和应用 | |
RU2568872C1 (ru) | Лекарственное средство для лечения вирусного гепатита с | |
CN102703369A (zh) | 一种制备ev71疫苗的重组双歧杆菌及其制备方法和应用 | |
US6130091A (en) | Method for obtaining a peptide derived from the respiratory syncytial virus polypeptide and bacterium expressing it | |
Zhou et al. | High throughput screening of scFv antibodies against viral hemorrhagic septicaemia virus by flow cytometry | |
AU5328599A (en) | Gastrointestinal bacterial antibody factories | |
Green | A Systematic Investigation of Anti-Phage Defense in Pseudomonas aeruginosa | |
Johnson | The Construction and Characterization of Vaccines Expressing the Pre-membrane and Glycoprotein E antigens of the West Nile Virus | |
Vaidya | Developing a Virus-Like Particle (VLP)-Based Vaccine for Neisseria gonorrhoeae | |
KR20150127266A (ko) | 디포신류 및 이들의 사용 방법 |